Literature DB >> 7510189

Palliative chemotherapy for advanced non-small cell lung cancer.

I E Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7510189      PMCID： PMC2539503          DOI： 10.1136/bmj.308.6926.429

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  Unresectable stage III non-small-cell lung cancer: lessons and directions from clinical trials research.

Authors:  M R Green
Journal:  J Natl Cancer Inst       Date:  1991-03-20       Impact factor: 13.506

2.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis.

Authors:  P J Souquet; F Chauvin; J P Boissel; R Cellerino; Y Cormier; P A Ganz; S Kaasa; J L Pater; E Quoix; E Rapp
Journal:  Lancet       Date:  1993-07-03       Impact factor: 79.321

3.  Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer.

Authors:  L Jaakkimainen; P J Goodwin; J Pater; P Warde; N Murray; E Rapp
Journal:  J Clin Oncol       Date:  1990-08       Impact factor: 44.544

4.  Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare.

Authors:  M H Cullen; R Joshi; A D Chetiyawardana; C M Woodroffe
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

5.  Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer.

Authors:  J R Hardy; T Noble; I E Smith
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

6.  Advanced breast cancer: use of resources and cost implications.

Authors:  M A Richards; S Braysher; W M Gregory; R D Rubens
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

7.  Primary systemic therapy for operable breast cancer.

Authors:  E D Anderson; A P Forrest; R A Hawkins; T J Anderson; R C Leonard; U Chetty
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640
  7 in total
  5 in total

Review 1.  Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.

Authors:  A Clegg; D A Scott; P Hewitson; M Sidhu; N Waugh
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

2.  Survival in advanced breast cancer. Combination chemotherapy improves outlook.

Authors:  L A Price
Journal:  BMJ       Date:  1994-04-23

3.  Chemotherapy in advanced small lung cell cancer.

Authors:  D R Ferry; M H Cullen
Journal:  BMJ       Date:  1994-04-02

4.  Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours.

Authors:  T W Beer; D C Rowlands; J Crocker
Journal:  Thorax       Date:  1996-05       Impact factor: 9.139

Review 5.  Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response.

Authors:  Matthew David Hale; Jeremy David Hayden; Heike Irmgard Grabsch
Journal:  Cell Oncol (Dordr)       Date:  2013-03-14       Impact factor: 6.730
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.